4D Molecular Therapeutics (FDMT) Earnings Date
Does this company deliver against its own promises? Earnings are a check on the thesis, not a catalyst to chase.
Estimate-vs-actual scoring began Aug 2026. Earlier quarters predate our snapshots, so their surprise stays "—". We never backfill an estimate we didn't observe.
| Report | Act EPS | Act rev | Reaction |
|---|---|---|---|
| Nov 10, 20258-K, before open · 8:17 am ET | −1.01 | $90,000.00 | −3.1%release day |
| Aug 11, 20258-K, before open · 8:05 am ET | −0.98 | $15,000.00 | −1.8%release day |
| May 8, 20258-K, after close · 4:16 pm ET | −0.86 | $0.00 | −4.9%next session |
| Jan 10, 20258-K, before open · 8:36 am ET | −0.90 | — | −5.5%release day |
| Nov 13, 20248-K, after close · 4:17 pm ET | −0.79 | $0.00 | +4.0%next session |
| Aug 8, 20248-K, after close · 4:14 pm ET | −0.63 | $0.00 | +0.5%next session |
| May 9, 20248-K, after close · 4:22 pm ET | −0.66 | $0.00 | +0.2%next session |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 5 | 2 | 7 | 6 |
| Avg estimate | −1.08 | −1.13 | −4.20 | −4.13 |
| Low estimate | −1.15 | −1.19 | −4.36 | −4.38 |
| High estimate | −1.03 | −1.06 | −4.07 | −3.53 |
| Year-ago EPS | — | — | −2.42 | −4.20E |
| Implied growth | — | — | — | — |
| Measure | Dec '26 | Mar '27 | FY26 | FY27 |
|---|---|---|---|---|
| No. of analysts | 4 | 2 | 5 | 5 |
| Avg estimate | $5.5M | $2.5M | $14.3M | $18.2M |
| Low estimate | $5.4M | $2.5M | $7.7M | $16.1M |
| High estimate | $5.5M | $2.5M | $18.1M | $20.3M |
| Year-ago revenue | — | — | $85.2M | $14.3ME |
| Implied growth | — | — | −83.3% | +27.7% |
| Snapshot age | Dec '26, period ending Dec 30, 2026 | Mar '27, period ending Mar 30, 2027 | FY26, period ending Dec 31, 2026 | FY27, period ending Dec 31, 2027 |
|---|---|---|---|---|
| Current estimate | −1.07 | −1.13 | −4.18 | −4.11 |
| 7 days ago | −1.06 | — | −4.15 | −4.09 |
| 30 days ago | −1.06 | — | −4.15 | −4.09 |
| 60 days ago | −1.04 | — | −4.14 | −4.09 |
| 90 days ago | −1.01 | — | −4.06 | −4.11 |
Estimate history accrues from our nightly snapshots. The 7/30/60/90-day rows fill in as tracking continues. Each column follows one fiscal period back through our snapshots; a dash means we had not recorded that period at that age. A rising bar makes a beat streak more meaningful; a falling one manufactures beats.
Dec '26 quarter consensus moved $−1.01 → $−1.08 over 90 tracked days, the same quarter at both ends. Per-analyst up/down revision counts aren't in our data feed. We show the bar's actual movement instead of guessing.
Common questions
What were 4D Molecular Therapeutics' latest quarterly earnings?
4D Molecular Therapeutics reported diluted EPS of −1.01 and revenue of $90,000.00 on Nov 10, 2025.
How did 4D Molecular Therapeutics' stock move after its last earnings report?
4D Molecular Therapeutics moved −3.1% in the session after its Nov 10, 2025 report.

